A pragmatic guide for management of adverse events associated with lorlatinib

Area of Science:

• Oncology
• Pharmacology

Background:

• Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) for ALK-positive metastatic non-small cell lung cancer (NSCLC).
• It demonstrates durable efficacy in treatment-naive and previously treated patients.
• Lorlatinib presents a distinct safety profile, including hyperlipidemia and CNS effects, compared to earlier ALK TKIs.

Purpose of the Study:

• To provide patient-focused recommendations for managing select adverse events (AEs) associated with lorlatinib.
• To offer a pragmatic approach for clinicians and nurses managing lorlatinib-related AEs in routine practice.
• To outline a
• prepare, monitor, manage, reassess
• framework for personalized patient care.

Main Methods:

• Development of recommendations by expert clinicians and nurses with extensive lorlatinib experience.
• Focus on practical, actionable strategies for AE evaluation and management.
• Utilizing clinical trial data and routine clinical practice insights.

Main Results:

• Most lorlatinib-associated AEs are manageable or reversible through dose adjustments or concomitant medications.
• Effective AE management can be achieved without compromising clinical efficacy or patient quality of life.
• The proposed framework facilitates streamlined and personalized AE management.

Conclusions:

• A structured approach to managing lorlatinib-associated AEs is essential for optimal patient outcomes.
• Patient-focused, pragmatic recommendations can effectively address the unique safety profile of lorlatinib.
• This guidance supports clinicians in maintaining treatment efficacy and quality of life for NSCLC patients receiving lorlatinib.